Radiative D∗D^* Decay Using Heavy Quark and Chiral Symmetry

The implications of chiral $SU(3)_L \times SU(3)_R$ symmetry and heavy quark symmetry for the radiative decays $D^{*0}\to D^0\gamma$, $D^{*+}\to D^+\gamma$, and $D_s^*\to D_s\gamma$ are discussed. Particular attention is paid to $SU(3)$ violating contributions of order $m_q^{1/2}$. Experimental data on these radiative decays provide constraints on the $D^* D\pi$ coupling.Comment: 9 pages plus 3 pages of figures in POSTSCRIPT file appended to TeX file (uses harvmac.tex and tables.tex), UCSD/PTH 92-31, CALT-68-1816, EFI-92-45, CERN-TH.6650/9

Comment on studying the corrections to factorization in B -> D(*) X

We propose studying the mechanism of factorization in exclusive decays of the form B->D(*)X by examining the differential decay rate as a function of the invariant mass of the light hadronic state X. If factorization works primarily due to the large N_c limit then its accuracy is not expected to decrease as the X invariant mass increases. However, if factorization is mostly a consequence of perturbative QCD then the corrections should grow with the X invariant mass. Combining data for hadronic tau decays and semileptonic B decays allows tests of factorization to be made for a variety of final states. We discuss the examples of B->D^*\pi^+\pi^-\pi^-\pi^0 and B->D^*\omega\pi^-. The mode B->D^*\omega\pi^- will allow a precision study of the dependence of the corrections to factorization on the invariant mass of the light hadronic state.Comment: 7 pages, minor clarifications to tex

Visual disorders and mal de debarquement syndrome : a potential comorbidity questionnaire-based study

Aim: Mal de debarquement syndrome (MdDS) is a neurological condition characterized by a constant sensation of self-motion; onset may be motion-triggered (MT) or non-motion-triggered/spontaneous (NMT/SO). People with MdDS experience similar symptoms to those with vertical heterophoria, a subset of binocular visual dysfunction. Hence, we aimed to explore potential visual symptom overlaps. Methods: MdDS patients (n=196) and controls (n=197) completed a visual health questionnaire. Results: Compared with controls, the MdDS group demonstrated higher visual disorder scores and visual complaints. NMT/SO participants reported unique visual symptoms and a higher prevalence of mild traumatic brain injury. Conclusion: Our findings suggest visual disorders may coexist with MdDS, particularly the NMT/SO subtype. The difference in visual dysfunction frequency and medical histories between subtypes, warrants further investigation into differing pathophysiological mechanisms. Plain language summary: MdDS is a condition where patients feel like they are always on a boat. It is typically triggered by passive motion-events (cruises, flights, etc.), but can develop after non-motion events. People with MdDS can experience symptoms like those with certain visual disorders, therefore we wanted to see if there were overlaps between these conditions. This study surveyed people with MdDS and individuals from the general population about visual health and found that the MdDS group reported a higher frequency of visual dysfunction symptoms. Compared with motion-triggered patients, non-motion patients reported unique visual symptoms. This demonstrates that visual disorders may coexist in MdDS. Tweetable abstract: Mal de debarquement syndrome #MdDS is a rare condition where patients feel like they are always on a boat. Given the overlap of symptoms between MdDS and a common visual disorder– these researchers turned their focus toward visual comorbidities and found some eye-raising results

Simple, Defensible Sample Sizes Based on Cost Efficiency -- With Discussion and Rejoinder

The conventional approach of choosing sample size to provide 80% or greater power ignores the cost implications of different sample size choices. Costs, however, are often impossible for investigators and funders to ignore in actual practice. Here, we propose and justify a new approach for choosing sample size based on cost efficiency, the ratio of a study’s projected scientific and/or practical value to its total cost. By showing that a study’s projected value exhibits diminishing marginal returns as a function of increasing sample size for a wide variety of definitions of study value, we are able to develop two simple choices that can be defended as more cost efficient than any larger sample size. The first is to choose the sample size that minimizes the average cost per subject. The second is to choose sample size to minimize total cost divided by the square root of sample size. This latter method is theoretically more justifiable for innovative studies, but also performs reasonably well and has some justification in other cases. For example, if projected study value is assumed to be proportional to power at a specific alternative and total cost is a linear function of sample size, then this approach is guaranteed either to produce more than 90% power or to be more cost efficient than any sample size that does. These methods are easy to implement, based on reliable inputs, and well justified, so they should be regarded as acceptable alternatives to current conventional approaches

Strong peak in Tc of Sr2RuO4 under uniaxial pressure

Sr2RuO4 is an unconventional superconductor that has attracted widespread study because of its high purity and the possibility that its superconducting order parameter has odd parity. We study the dependence of its superconductivity on anisotropic strain. Applying uniaxial pressures of up to ~1 gigapascals along a 〈100〉 direction (a axis) of the crystal lattice results in the transition temperature (Tc) increasing from 1.5 kelvin in the unstrained material to 3.4 kelvin at compression by ≈0.6%, and then falling steeply. Calculations give evidence that the observed maximum Tc occurs at or near a Lifshitz transition when the Fermi level passes through a Van Hove singularity, and open the possibility that the highly strained, Tc = 3.4 K Sr2RuO4 has an even-parity, rather than an odd-parity, order parameter.PostprintPeer reviewe

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan

A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan

1Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantablecardioverter defibrillators to reduce patient morbidity [NCT00279279]

BACKGROUND: Implantable Cardioverter Defibrillator (ICD) therapy has been proven to be beneficial and efficacious for the treatment of serious ventricular tachyarrhythmias in primary prevention patients. However, primary prevention patients appear to have a lower incidence of ventricular arrhythmias in comparison to secondary prevention patients and consequently likely experience a higher proportion of detections due to supraventricular arrhythmias. Recent trials have demonstrated that strategic and specific programming choices reduce the number of inappropriate shocks and that anti-tachycardia pacing (ATP) is an effective alternative to shock therapy for many sustained ventricular arrhythmias. METHODS: The Primary Prevention Parameters Evaluation (PREPARE) study is a multi-center cohort study, evaluating the efficacy of a pre-specified strategic profile of VT/VF detection and therapy settings in 700 primary prevention patients in an effort to safely reduce the number of shock therapies delivered. The patients, both with and without cardiac resynchronization therapy, are compared to a well-qualified set (n = 691) of historical controls derived from the MIRACLE ICD and EMPIRIC trials. This manuscript describes the design of the PREPARE study. The study results, to be presented separately, will characterize the efficacy of this programming set (PREPARE) compared with physician-tailored programming (MIRACLE ICD and EMPIRIC)

Semileptonic B decays to excited charmed mesons

Exclusive semileptonic B decays into excited charmed mesons are investigated at order $\Lambda_{QCD}/m_Q$ in the heavy quark effective theory. Differential decay rates for each helicity state of the four lightest excited $D$ mesons ($D_1$, $D_2^*$, $D_0^*$, and $D_1^*$) are examined. At zero recoil, $\Lambda_{QCD}/m_Q$ corrections to the matrix elements of the weak currents can be written in terms of the leading Isgur-Wise functions for the corresponding transition and meson mass splittings. A model independent prediction is found for the slope parameter of the decay rate into helicity zero $D_1$ at zero recoil. The differential decay rates are predicted, including $\Lambda_{QCD}/m_Q$ corrections with some model dependence away from zero recoil and including order $\alpha_s$ corrections. Ratios of various exclusive branching ratios are computed. Matrix elements of the weak currents between $B$ mesons and other excited charmed mesons are discussed at zero recoil to order $\Lambda_{QCD}/m_Q$. These amplitudes vanish at leading order, and can be written at order $\Lambda_{QCD}/m_Q$ in terms of local matrix elements. Applications to $B$ decay sum rules and factorization are presented.Comment: 39 pages revtex including 10 figures, uses epsf. Substantial improvements throughout the pape

Treatment Guidelines for Hyponatremia Stay the Course

International guidelines designed to minimize the risk of complications that can occur when correcting severe hyponatremia have been widely accepted for a decade. On the basis of the results of a recent large retrospective study of patients hospitalized with hyponatremia, it has been suggested that hyponatremia guidelines have gone too far in limiting the rate of rise of the serum sodium concentration; the need for therapeutic caution and frequent monitoring of the serum sodium concentration has been questioned. These assertions are reminiscent of a controversy that began many years ago. After reviewing the history of that controversy, the evidence supporting the guidelines, and the validity of data challenging them, we conclude that current safeguards should not be abandoned. To do so would be akin to discarding your umbrella because you remained dry in a rainstorm. The authors of this review, who represent 20 medical centers in nine countries, have all contributed significantly to the literature on the subject. We urge clinicians to continue to treat severe hyponatremia cautiously and to wait for better evidence before adopting less stringent therapeutic limits.</p